The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines Federico Zamberlan, Camila Sanz, Rocío Martínez Vivot, Carla Pallavicini, Fire Erowid, Earth Erowid and Enzo Tagliazucchi Frontiers in Integrative Neuroscience, 2018, 12, 54. doi : 10.3389/fnint.2018.00054 Classic psychedelics are substances of paramount cultural and neuroscientific importance. A distinctive feature of psychedelic drugs is the wide range of potential subjective effects they can elicit, known to be deeply influenced by the internal state of the user (“set”) and the surroundings (“setting”). The observation of crosstolerance and a series [...]
Lire la suiteModern Clinical Research on LSD Matthias E Liechti Neuropsychopharmacology, 2017, 42, 2114–2127. doi : 10.1038/npp.2017.86 All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are reviewed herein. There were five recent studies in healthy participants and one in patients. In a controlled setting, LSD acutely induced bliss, audiovisual synesthesia, altered meaning of perceptions, derealization, depersonalization, and mystical experiences. These subjective effects of LSD were mediated by the 5-HT2A receptor. LSD increased feelings of closeness to others, openness, trust, and suggestibility. LSD impaired the recognition of sad and fearful faces, reduced left [...]
Lire la suitePsychedelics and potential benefits in “healthy normals”: A review of the literature Sam GANDY Journal of Psychedelic Studies, 2019, 3, (3), 280–287. Doi : 10.1556/2054.2019.029 We are in the midst of a psychedelic research renaissance. With research examining the efficacy of psychedelics as a treatment for a range of mental health indications still in its early stages, there is an increasing body of research to show that careful use of psychedelics can yield a variety of benefits in “healthy normals” and so lead to “the betterment of well people.” Psychedelics have been found to modulate neuroplasticity, and usage in a supportive setting can result [...]
Lire la suiteNeurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression Paulo R. Shiroma, C. Sophia Albott, Brian Johns, Paul Thuras, Joseph Wels and Kelvin O. Lim The International Journal of Neuropsychopharmacology, 2014, Volume 17, Issue 11, 1805–1813, Doi : 10.1017/S1461145714001011 Abstract The N-methyl-D-aspartate glutamate receptor antagonist ketamine has demonstrated rapid anti-depressant effects in treatment-resistant depression (TRD). However, evaluation of ketamine's neurocognitive aspects in TRD has started to be explored. This study aims to (1) examine baseline neurocognitive performance and change in severity of depressive symptoms through six ketamine infusions, (2) examine the neurocognitive effects after completion of serial infusions and whether changes were associated to [...]
Lire la suiteThe therapeutic role of Cannabidiol in mental health : a systematic review Rabia Khan, Sadiq Naveed, Nadeem Mian, Ania Fida, Muhammad Abdur Raafey and Kapil Kiran Aedma Journal of Cannabis Research, 2020, 2, 2 doi : 10.1186/s42238-019-0012-y Abstract Background : The therapeutic application of cannabidiol (CBD) is gaining interest due to expanding evidence for its use. Objective : To summarize the clinical outcomes, study designs and limitations for the use of CBD and nabiximols (whole plant extract from Cannabis sativa L. that has been purified into 1:1 ratio of CBD and delta-9- tetrahydrocannabinol) in the treatment of psychiatric disorders. Materials and method : A systematic review was [...]
Lire la suiteLe cannabidiol, un agent thérapeutique prometteur ? Benjamin Rolland , Mathieu Chappuy, Patrizia Carrieri SWAPS, 3e et 4e trimestre 2019, n° 92-93, , 5-6. Deuxième cannabinoïde le plus étudié après le THC, sans effet psychoactif, le cannabidiol dispose de propriétés thérapeutiques intéressantes, notamment en psychiatrie. Le point sur les recherches La grande famille des cannabinoïdes Les cannabinoïdes sont un ensemble de substances capables d’activer les récepteurs du même nom (« récepteurs cannabinoïdes »). Il existe deux grandes familles de récepteurs cannabinoïdes, CB1 et CB2. Dans le système nerveux central, c’est surtout CB1 qui est exprimé, alors que CB2 est principalement présent dans le système immunitaire. [...]
Lire la suiteA novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol : Δ9-Tetrahydrocannabiphorol Cinzia Citti, Pasquale Linciano, Fabiana Russo, Livio Luongo, Monica Iannotta, Sabatino Maione, Aldo Laganà, Anna Laura Capriotti, Flavio Forni, Maria Angela Vandelli, Giuseppe Gigli & Giuseppe Cannazza Scientific Reports | (2019) 9:20335 | www.nature.com/scientificreports Doi : 10.1038/s41598-019-56785-1 (-)-Trans-Δ9-tetrahydrocannabinol (Δ9-THC) is the main compound responsible for the intoxicant activity of Cannabis sativa L. The length of the side alkyl chain influences the biological activity of this cannabinoid. In particular, synthetic analogues of Δ9-THC with a longer side chain have shown cannabimimetic properties far higher than Δ9-THC [...]
Lire la suiteIsolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa Mohamed M. Radwan, Mahmoud A. ElSohly, Abir T. El-Alfy, Safwat A. Ahmed, Desmond Slade, Afeef S. Husni, Susan P. Manly, Lisa Wilson, Suzanne Seale, Stephen J. Cutler, and Samir A. Ross Journal of Natural Products, 2015 June 26, 78, (6), 1271–1276. doi : 10.1021/acs.jnatprod.5b00065 Abstract Seven new naturally occurring hydroxylated cannabinoids (1–7), along with the known cannabiripsol (8), have been isolated from the aerial parts of high-potency Cannabis sativa. The structures of the new compounds were determined by 1D and 2D NMR spectroscopic analysis, GC-MS, and HRESIMS as 8α hydroxy-Δ9-tetrahydrocannabinol (1), 8β-hydroxy-Δ9-tetrahydrocannabinol (2), 10α-hydroxy-Δ8 [...]
Lire la suiteLe THCP : un nouveau cannabinoïde 33 fois plus fort que le THC Blog-cannabis.fr, 31 décembre 2019 https://www.blog-cannabis.fr/2019/12/31/thcp-nouveau-cannabinoide/ Un nouveau phytocannabinoïde isolé du Cannabis sativa L avec une activité cannabimimétique 30 fois supérieure au THC a été détecté dans le cannabis Le cannabinoïde végétal Tetrahydrocannabiphorol ( THCP ) le plus puissant au monde a récemment été découvert dans une étude en Italie. Il est presque identique dans sa structure au THC mais est 33 fois plus fort que lui, ainsi que du CBDP, le dérivé correspondant du CBD. La recherche pourrait permettre de développer de futures souches de THCP beaucoup plus puissantes. Jusqu’à présent, près de 150 [...]
Lire la suiteA systematic study of microdosing psychedelics RESEARCH ARTICLE Vince Polito, Richard J. Stevenson PLoS ONE, 2019, 14, (2), e0211023. Doi : 10.1371/journal.pone.0211023 Abstract The phenomenon of ‘microdosing’, that is, regular ingestion of very small quantities of psychedelic substances, has seen a rapid explosion of popularity in recent years. Individuals who microdose report minimal acute effects from these substances yet claim a range of long-term general health and wellbeing benefits. There have been no published empirical studies of microdosing and the current legal and bureaucratic climate makes direct empirical investigation of the effects of psychedelics difficult. In Study One we conducted a systematic, observational investigation of individuals [...]
Lire la suite